Cargando…

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

INTRODUCTION: Metastasis involves the accumulation of genetic and epigenetic alterations leading to activation of prometastatic genes and inactivation of antimetastatic genes. Among epigenetic alterations, DNA hypermethylation and histone hypoacetylation are the focus of intense translational resear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Cárdenas, Enrique, Taja-Chayeb, Lucía, Trejo-Becerril, Catalina, Chanona-Vilchis, José, Chávez-Blanco, Alma, Domínguez-Gómez, Guadalupe, Langley, Elizabeth, García-Carrancá, Alejandro, Dueñas-González, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290866/ https://www.ncbi.nlm.nih.gov/pubmed/30584338 http://dx.doi.org/10.2147/OTT.S187306

Ejemplares similares

Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
Publicado: (2022)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers
por: Bauman, Julie, et al.
Publicado: (2014)

Transformation of NIH3T3 Cells with Synthetic c‐Ha‐ras Genes
por: Kamiya, Hiroyuki, et al.
Publicado: (1989)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

Selective activation of oncogenic Ha-ras-induced apoptosis in NIH/3T3 cells
Publicado: (1998)

Selective activation of oncogenic Ha-ras-induced apoptosis in NIH/3T3 cells.
por: Liu, H. S., et al.
Publicado: (1998)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2006)

Reversal of increased mammary tumorigenesis by valproic acid and hydralazine in offspring of dams fed high fat diet during pregnancy
por: Andrade, F. de Oliveira, et al.
Publicado: (2019)

Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells
por: Ronen, S M, et al.
Publicado: (2001)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition
por: Hanker, Ariella B, et al.
Publicado: (2009)

Up-regulation of HLA class I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2007)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes.
por: Niimi, S., et al.
Publicado: (1991)

Restriction Enzyme Analysis of DNA Methylation in “Condensed” Chromatin of Ha-Ras-Transformed NIH 3T3 Cells
por: Mello, Maria Luiza S., et al.
Publicado: (2000)

Hydralazine-Induced Vasculitis
por: Gandhi, Pulkit, et al.
Publicado: (2023)

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
por: Zuckerman, Roman, et al.
Publicado: (2018)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Effective models for antimetastatic therapies
por: Tian, Lin, et al.
Publicado: (2017)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells
por: Park, Young Jae, et al.
Publicado: (2014)

Hydralazine-Induced Vasculitis With Gastrointestinal Pseudomelanosis
por: Novikov, Aleksey, et al.
Publicado: (2014)

Clinical Characteristics of Hydralazine-induced Lupus
por: Timlin, Homa, et al.
Publicado: (2019)

Hydralazine-Induced Isolated Lupus Nephritis
por: Khan, Naseer, et al.
Publicado: (2020)

Hydralazine-Associated Vasculitis and Pulmonary Hemorrhage
por: Strubchevska, Kateryna, et al.
Publicado: (2023)

Induction of MAP kinase phosphatase 3 through Erk/MAP kinase activation in three oncogenic Ras (H-, K- and N-Ras)-expressing NIH/3T3 mouse embryonic fibroblast cell lines
por: Koo, JaeHyung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vcr0b7eed87lpb10cs49j6elf5